Objectives
The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development.
The objectives of the SIG are:
- To share (anonymized) case studies of how quantitative decision-making methods have been used within pharmaceutical companies, for decisions at the trial level, at the development level and at the portfolio level
- To perform literature reviews, discuss and make recommendations on existing methodologies in terms of approach and interpretation
- To develop new methodologies or practices where needed
- To promote the role of the statistician in supporting decision-making in pharmaceutical companies and/or other stakeholders
- To propose trainings, public meetings or publications to share methods and experience
Who we are
Thomas Blondel (Ceva) |
Nicolas Bonnet (Sanofi) |
Daniel Bratton (GSK) |
Sarah Bray (Amgen) |
Alex Carlton (GSK) (Co-Chair) |
Jacquie Christie (Sobi) |
Paul Frewer (AstraZeneca) |
Heiko Goette (Merck) |
Tadhg Guerin (Theravance) (Co-Chair) |
Kimberley Hacquoil (Exploristics) |
Martin Johnson (UCB Pharma) |
Kevin Kunzmann (Boehringer Ingelheim) |
John-Philip Lawo (CSL Behring) |
Daniel Leibovitz (Incyte) |
Jesper Madsen (Novo Nordisk) |
Pavel Mozgunov (Cambridge University) |
Emmanuel Pham (Nova Discovery) |
Gustaf Rydevik (UCB Pharma) |
Gaëlle Saint-Hilary (Saryga) |
Guido Thömmes (Grunenthal) |
Katie Thorn (GSK) |
Stefano Vezzoli (Chiesi Farmaceutici) |
Stig Johan Wiklund |
How to get in touch
For further information, or to join the QDM SIG, please contact our Co-Chairs:
Alex Carlton (GSK) alex.l.carlton@gsk.com
Tadhg Guerin (Theravance) tguerin@theravance.com
Latest News
...
Upcoming Events
...